Peer-Reviewed Publications

      A network-based approach to quantifying the impact of biologically active substances

      Hoeng, J.; Deehan, R.; Pratt, D.; Martin, F.; Sewer, A.; Thomson, T. M.; Drubin, D. A.; Waters, C. A.; de Graaf, D.; Peitsch, M. C.
      Published
      Dec 1, 2011
      DOI
      10.1016/j.drudis.2011.11.008
      PMID
      22155224
      Link to publication
      Topic
      Summary

      Society increasingly demands close scrutiny of the potential health risks of long-term exposure to biologically active substances, such as therapeutic drugs or environmental toxins. Such risks are typically assessed a posteriori through clinical epidemiology studies. However, disease might take decades to manifest, at a point where changes in therapeutic regime, life style or exposure would not prevent disease onset.

      Related Publications

      Quantitative Adverse Outcome Pathway: A New Prediction Tool to Assess Human Risk of Decreased Lung Function When Switching from Combustible Cigarettes to Heated Tobacco Products

      Systems Toxicology

      An In Vitro Systems Toxicology Assessment of Novel Electronic Vapor Device by Using Air–Liquid Interface Buccal, Bronchial, Small Airway, and Alveolar Culture Models

      Systems Toxicology

      Blood and urine multi-omics analysis of the impact of e-vaping, smoking, and cessation: from exposome to molecular responses

      Systems Toxicology

      Quantitative Modeling of In Vitro Data Using an Adverse Outcome Pathway for the Risk Assessment of Decreased Lung Function in Humans

      Systems Toxicology

      Systems toxicology: The future of risk assessment

      Systems Toxicology

      Systems biology: Methods and applications

      Systems Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.